Therapeutic Solutions International Awards Distribution of NanoStilbene and Nano Cannabidiol in Mexico to Immun ET Laboratories, LLC.
NanoStilbene Shown to Enhance Anticancer Immunity in Cancer Patients through Modulation of Inflammatory Mediators
OCEANSIDE, CA -- May 6, 2019 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today a sales agreement for the exclusive distribution of NanoStilbene and Nano Cannabidiol throughout Mexico with Immun ET.
TSOI recently announced preliminary data for immune stimulation in advanced cancer patients with NanoStilbene, a nanoemulsion of nanoparticle pterostilbene that is taken orally. Daily treatment with NanoStilbene caused a reduction in serum levels of inflammatory markers TNF-alpha, IL-6, and CRP. Assessment of peripheral blood mononuclear cell ability to generate IFN-gamma subsequent to stimulation with anti-CD3 and anti-CD28 was increased. Additionally, NK cytotoxicity was augmented.
These results suggest that NanoStilbene may be a useful adjuvant to immunotherapy of cancer rescuing T cell and NK cell activities. Augmentation of NK cell function may stimulate efficacy of approved therapies that depend on an active NK compartment such as Herceptin, Rituximab, and Cetuximab.
The Nano Cannabidiol product we have produced is built upon the same nano particle platform as NanoStilbene. This provides for good protection and oral delivery system, the nanoemulsion for cannabidiol isolate uses the same low-energy emulsification method as NanoStilbene. Nanoemulsions are non-equilibrium systems and possess kinetic stability in a long period with a remarkable small droplet size (below 200 nm).
The cannabidiol isolate (which contains zero THC, and zero Terpenes) we place in the nanodroplet is free from air, light, and hard environment and contains 200mg of >99% pure isolate per milliliter of liquid. Typical clinical doses of cannabidiol are in the range of 15-20mg daily. 2 drops of our Nano Cannabidiol provides 20mg.
"We are pleased to make this announcement today for Immun ET Laboratories to have exclusive distribution rights for NanoStilbene and Nano Cannabidiol throughout all of Mexico" said Tim G Dixon CEO & President of Therapeutic Solutions International, Inc. "Having worked closely with the principal of Immun ET, Dr. Javier Lopez, for many years in advanced cancer studies where in 2015 we conducted our 10 patient StemVacs immunotherapy clinical trial, we are excited to continue our long-standing relationship further solidified by this award announced today."
"Immun ET is very excited to offer both of these nano particle compounds from TSOI to our customers in both their original form and in various blends together we are calling NanoVita and NanoVita Plus. Having the privilege to observe all of the work in developing NanoStilbene, essentially from bench to bedside, including a pharmacokinetic study and a clinical trial of advanced cancer patients, we have eagerly awaited this day to be able to provide this patented immune adjuvant to cancer patients in Mexico" said Dr. Javier Lopez, Chief Executive Officer of Immun ET Laboratories. "And in addition, having the ability to distribute exclusively their Nano Cannabidiol in Mexico as well, gives us two very potent and highly concentrated formulations to meet a variety of clinical needs" added Dr. Lopez.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on NanoStilbene visit www.nanostilbene.com.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
About Immun ET Laboratories, LLC.
Immun ET focuses on the development and commercialization of immunological and regenerative therapies to cover medical needs.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.